![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsors and Collaborators: |
Bristol-Myers Squibb Otsuka America Pharmaceutical |
---|---|
Information provided by: | Bristol-Myers Squibb |
ClinicalTrials.gov Identifier: | NCT00329810 |
To evaluate the effectiveness of Aripiprazole after 12 weeks of therapy for Schizophrenic patients.
Condition | Intervention | Phase |
---|---|---|
Schizophrenia |
Drug: Aripiprazole |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Prospective, Multicenter, Open-Label Study to Evaluate the Effectiveness and the Effect on Cognitive Function of a Treatment With Aripiprazole in a Board Range of Schizophrenic Patients |
Estimated Enrollment: | 500 |
Study Start Date: | March 2005 |
Arms | Assigned Interventions |
---|---|
Switch: Active Comparator |
Drug: Aripiprazole
Tablets, oral, 15 mg, once daily, 12 weeks.
|
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | CN138-166 |
Study First Received: | September 12, 2005 |
Last Updated: | June 27, 2008 |
ClinicalTrials.gov Identifier: | NCT00329810 History of Changes |
Health Authority: | Belgium: Institutional Review Board |
Schizophrenia Tranquilizing Agents Mental Disorders Psychotropic Drugs Central Nervous System Depressants |
Psychotic Disorders Aripiprazole Antipsychotic Agents Schizophrenia and Disorders with Psychotic Features |
Schizophrenia Tranquilizing Agents Mental Disorders Therapeutic Uses Physiological Effects of Drugs Psychotropic Drugs |
Central Nervous System Depressants Aripiprazole Antipsychotic Agents Central Nervous System Agents Pharmacologic Actions Schizophrenia and Disorders with Psychotic Features |